SU 5220
Alternative Names: NeoasterriquinoneLatest Information Update: 29 Feb 2008
At a glance
- Originator MDS Pharma Services; SUGEN; University of Michigan Medical School
- Class Indoles; Quinones; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; GRB2 protein inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Jun 2002 No development reported - Preclinical for Cancer in USA (unspecified route)
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 13 Oct 1999 Preclinical development for Cancer in USA (Unknown route)